Related Experiment Video

Updated: Mar 29, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

An emerging role for cytopathology in precision oncology

Chantal Pauli1,2, Loredana Puca1,2, Juan Miguel Mosquera1,2

  • 1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

Cancer Cytopathology
|December 8, 2015
PubMed

Insights

Patient-derived tumor organoids enable personalized cancer treatment and drug resistance studies. Cytology offers a cost-effective quality control for molecular testing in precision medicine.

Area of Science:

  • Oncology
  • Genomics
  • Biotechnology

Background:

  • Precision medicine tailors disease prevention and treatment to individual variability in genes, environment, and lifestyle.
  • The Englander Institute for Precision Medicine developed a program for patient-derived, 3D tumor organoids.
  • These organoids are used for tumor-specific drug testing, treatment strategy tailoring, and drug resistance modeling.

Purpose of the Study:

  • To outline and discuss platforms for characterizing and validating patient-derived, 3D tumor organoids.
  • To illustrate the role of cytology as a cost-effective quality control measure in precision medicine.

Main Methods:

  • Development of a program to grow patient-derived, 3D tumor organoids.
  • Utilizing routine cytology preparations for molecular testing.
  • Characterization and validation of tumor organoids using various platforms.

Main Results:

  • Patient-derived 3D tumor organoids serve as valuable models for personalized drug testing and resistance studies.
  • Cytology preparations are effective and economical for molecular testing.
  • Established platforms facilitate the characterization and validation of these organoids.

Conclusions:

  • Patient-derived 3D tumor organoids are crucial for advancing precision medicine.
  • Cytology provides a vital, cost-effective quality control in the era of personalized molecular diagnostics.
Keywords:
3-dimensional (3D) tumor organoidcytologycytology smearin vitro modelsnext-generation sequencingorganoidsprecision medicine

More Related Videos

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology07:03

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

1.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.3K